Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Poirier

Showing results (91-100 of 115) with videos related to

Pageof 12
Sort By:
Cancer Research|November 24, 2021
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line ChemotherapyAlvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yuan Hao, et al.
Cancer Discovery|August 4, 2021
Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung CancerMetamia Ciampricotti, Triantafyllia Karakousi, Allison L Richards, et al.
Cell Reports|October 27, 2023
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistanceAnastasia-Maria Zavitsanou, Ray Pillai, Yuan Hao, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerRay Pillai, Sarah E LeBoeuf, Yuan Hao, et al.
Cancer Research|July 11, 2020
Epigenetic CRISPR Screens Identify <i>Npm1</i> as a Therapeutic Vulnerability in Non-Small Cell Lung CancerFei Li, Wai-Lung Ng, Troy A Luster, et al.
Science Advances|March 27, 2024
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerRay Pillai, Sarah E LeBoeuf, Yuan Hao, et al.
Science (New York, N.Y.)|October 14, 2021
Replication and single-cycle delivery of SARS-CoV-2 repliconsInna Ricardo-Lax, Joseph M Luna, Tran Thi Nhu Thao, et al.
Nature Communications|August 4, 2019
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancerMarcel A Dammert, Johannes Brägelmann, Rachelle R Olsen, et al.
Biorxiv : the Preprint Server for Biology|May 3, 2023
<i>In vivo</i> metabolomics identifies CD38 as an emergent vulnerability in <i>LKB1</i> -mutant lung cancerJiehui Deng, David H Peng, David Fenyo, et al.
Nature Medicine|October 3, 2017
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysisRodrigo Romero, Volkan I Sayin, Shawn M Davidson, et al.
Pageof 12

Showing results (91-100 of 115) with videos related to

Sort By:
Pageof 12
Cancer Research|November 24, 2021
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line ChemotherapyAlvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yuan Hao, et al.
Cancer Discovery|August 4, 2021
Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung CancerMetamia Ciampricotti, Triantafyllia Karakousi, Allison L Richards, et al.
Cell Reports|October 27, 2023
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistanceAnastasia-Maria Zavitsanou, Ray Pillai, Yuan Hao, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerRay Pillai, Sarah E LeBoeuf, Yuan Hao, et al.
Cancer Research|July 11, 2020
Epigenetic CRISPR Screens Identify <i>Npm1</i> as a Therapeutic Vulnerability in Non-Small Cell Lung CancerFei Li, Wai-Lung Ng, Troy A Luster, et al.
Science Advances|March 27, 2024
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerRay Pillai, Sarah E LeBoeuf, Yuan Hao, et al.
Science (New York, N.Y.)|October 14, 2021
Replication and single-cycle delivery of SARS-CoV-2 repliconsInna Ricardo-Lax, Joseph M Luna, Tran Thi Nhu Thao, et al.
Nature Communications|August 4, 2019
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancerMarcel A Dammert, Johannes Brägelmann, Rachelle R Olsen, et al.
Biorxiv : the Preprint Server for Biology|May 3, 2023
<i>In vivo</i> metabolomics identifies CD38 as an emergent vulnerability in <i>LKB1</i> -mutant lung cancerJiehui Deng, David H Peng, David Fenyo, et al.
Nature Medicine|October 3, 2017
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysisRodrigo Romero, Volkan I Sayin, Shawn M Davidson, et al.
Pageof 12